HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy
- PMID: 10025799
- DOI: 10.1212/wnl.52.3.623
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy
Abstract
Introduction of highly active antiretroviral therapy (HAART) has been associated with many changes in the complications of human immunodeficiency virus (HIV) infection. A cohort of 25 HIV patients with progressive multifocal leukoencephalopathy (PML) treated with HAART experienced a median survival of >46 weeks. This is an improvement in prognosis compared with recent historic experience and correlated with HIV RNA viral load reductions. We conclude that current HIV therapy is important in improving the outlook of PML in the setting of HIV.
Comment in
-
Gaining ground in progressive multifocal leukoencephalopathy.Neurology. 1999 Feb;52(3):440-1. doi: 10.1212/wnl.52.3.440. Neurology. 1999. PMID: 10025768 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical